psoriasis
Conditions
Interventions
Treatment group:Secukinumab+Huoxue Xiaoyin Decoction+Xueluo Triple Therapy(Thread-embedding+Intradermal needles+Auricular points)
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female aged 18–75 years; 2. Diagnosed with plaque psoriasis for =6 months; 3. At baseline, Physician's Global Assessment =3, Psoriasis Area and Severity Index =12, and Body Surface Area involved =10%; 4. Meet the manifestations of psoriasis with blood stasis and collateral obstruction (syndrome pertaining to skin collaterals); 5. The patient or family member voluntarily signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Psoriasis-related medication history: topical medication history within the previous 2 weeks, traditional Chinese medicine medication history within the previous 1 month, non-biologic systemic medication history or phototherapy history within the previous 1 month; biologic medication history within the previous 2 months. 2. History of other systemic diseases such as malignant tumors, coronary heart disease, etc. 3. History of hepatitis B, tuberculosis, human immunodeficiency virus (HIV), and chronic, opportunistic, and severe infections. 4. Pregnant or breastfeeding women. 5. Participation in other clinical trials within the previous month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse rate;Percentage of patients achieving Psoriasis Area and Severity Index 75/90/100 at week 24;Improvement rate of TCM syndrome score (at Week 24 / Week 48);Dermatology Life Quality Index response rate; | — |
Countries
China
Contacts
Public ContactYanping Bai
China-Japan Friendship Hospital
Outcome results
None listed